Clinical efficacy and safety of cefepime in febrile neutropenic patients with lung cancer

Journal of Infection and Chemotherapy

Volumn 16, Issue 2, 2010, Pages 113-117

  Fujita, Masaki ^a,b   Ouchi, Hiroshi ^c   Inoue, Yuichi ^d   Inoshima, Ichiro ^a   Ohshima, Tsukasa ^c   Yoshimura, Chikara ^b   Wataya, Hiroshi ^e   Kawasaki, Masayuki ^f   Tokunaga, Shoji ^g   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^c KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^d Isahaya Health Insurance General Hospital   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION   (Japan)

^g KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cefepime; Empiric monotherapy; Febrile neutropenia; Lung cancer

Indexed keywords

CARBAPENEM; CEFEPIME;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; JAPAN; LUNG CANCER; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPHIL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; THORAX PAIN;

EID: 77952238282     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-010-0030-3     Document Type: Article

References (17)

1. J Klastersky 1993 Febrile neutropenia Curr Opin Oncol 5 625 632 1:STN:280:DyaK3sznt1Wmtg%3D%3D 8364078
2. WT Hughes D Armstrong GP Bodey EJ Bow AE Brown T Calandra, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 34 730 751 10.1086/339215 11850858 (Pubitemid 34194843)
3. T Masaoka 2004 Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary Clin Infect Dis 39 S49 S52 10.1086/383054 15250021 (Pubitemid 38971476)
4. S Niho Y Ohe K Goto H Ohmatsu T Matsumoto K Kubota, et al. 2004 Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer Jpn J Clin Oncol 34 69 73 10.1093/jjco/hyh019 15067098 (Pubitemid 43115321)
5. J Klastersky M Paesmans EB Rubenstein M Boyer L Elting R Feld, et al. 2000 The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Clin Oncol 18 3038 3051 1:STN:280:DC%2BD3cvivFCrsg%3D%3D 10944139
6. D Yamamura R Gucalp P Carlisle M Cimino J Roberts C Rotstein 1997 Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients Antimicrob Agents Chemother 41 1704 1708 1:CAS:528:DyaK2sXlt1Cgtrg%3D 9257745
7. P Biron C Fuhrmann H Cure P Viens D Lefebvre A Thyss, et al. 1998 Cefepeme versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia J Antimicrob Chemother 42 511 518 10.1093/jac/42.4.511 1:CAS:528:DyaK1cXmslyhs7Y%3D 9818751 (Pubitemid 28473012)
8. II Raad C Escalante RY Hachem HA Hanna R Husni C Afif, et al. 2003 Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime Cancer 98 1039 1047 10.1002/cncr.11613 1:CAS:528:DC%2BD3sXns1Sjsbw%3D 12942573 (Pubitemid 37022106)
9. H Cherif M Björkholm P Engervall P Johansson P Ljungman R Hast, et al. 2004 A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies Scand J Infect Dis 36 593 600 10.1080/00365540410017590 1:CAS:528:DC%2BD2cXmsV2htr8%3D 15370671 (Pubitemid 39247980)
10. EJ Bow C Rotstein GA Noskin M Laverdiere AP Schwarer BH Segal, et al. 2006 A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies Clin Infect Dis 43 447 459 10.1086/505393 1:CAS:528:DC%2BD28XovFWgs7o%3D 16838234 (Pubitemid 44157153)
11. H Ariffin CL Ai CL Lee WA Abdullah 2006 Cefepime monotherapy for treatment of febrile neutropenia in children J Paediatr Child Health 42 781 784 10.1111/j.1440-1754.2006.00977.x 17096713 (Pubitemid 44690824)
12. N Hanna FA Shepherd FV Fossella JR Pereira F de Marinis J von Pawel, et al. 2004 Randomized phase III trial of pemetrexed vs. docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597 10.1200/JCO.2004.08.163 1:CAS:528:DC%2BD2cXpsVWmurk%3D 15117980 (Pubitemid 41079796)
13. A Wailoo A Sutton A Morgan 2009 The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis Br J Cancer 100 436 441 10.1038/sj.bjc.6604863 1:CAS:528:DC%2BD1MXhsFekt74%3D 19190633
14. KT Kwon HS Cheong JY Rhee YM Wi SY Ryu ST Heo, et al. 2008 Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial Jpn J Clin Oncol 38 49 55 10.1093/jjco/hym151 18203711 (Pubitemid 351248120)
15. K Tamura H Matsuoka J Tsukada M Masuda S Ikeda E Matsuishi, et al. 2002 Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study Am J Hematol 71 248 255 10.1002/ajh.10236 1:CAS:528: DC%2BD38Xps1Ortr8%3D 12447952 (Pubitemid 35396940)
16. K Tamura K Imajo N Akiyama K Suzuki A Urabe K Ohyashiki, et al. 2004 Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia Clin Infect Dis 39 S15 S24 10.1086/383046 1:CAS:528:DC%2BD2cXntVahs78%3D 15250016 (Pubitemid 38971471)
17. N Ohmagari H Hanna L Graviss B Hackett C Perego V Gonzalez, et al. 2005 Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer Cancer 104 205 212 10.1002/cncr.21115 15880433 (Pubitemid 40847770)